SYNCOM FORMULATIONS (INDIA)
Back to Balance Sheet
|
SYNCOM FORMULATIONS (INDIA) Last 5 Year Total Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2017 | Mar2016 | |
---|---|---|---|---|---|
Total Liabilities | ₹405 Cr | ₹378 Cr | ₹308 Cr | ₹184 Cr | ₹181 Cr |
What is the latest Total Liabilities ratio of SYNCOM FORMULATIONS (INDIA) ?
Year | Total Liabilities |
---|---|
Mar2024 | ₹405 Cr |
Mar2023 | ₹378 Cr |
Mar2022 | ₹308 Cr |
Mar2017 | ₹184 Cr |
Mar2016 | ₹181 Cr |
How is Total Liabilities of SYNCOM FORMULATIONS (INDIA) Trending?
Years | Total Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹405 Cr | 7.10 | |
Mar2023 | ₹378 Cr | 22.58 | |
Mar2022 | ₹308 Cr | 67.59 | |
Mar2017 | ₹184 Cr | 1.81 | |
Mar2016 | ₹181 Cr | - |
Compare Total Liabilities of peers of SYNCOM FORMULATIONS (INDIA)
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
SYNCOM FORMULATIONS (INDIA) | ₹1,616.8 Cr | 1.5% | -4.1% | -17.9% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹379,191.0 Cr | 1% | -0.9% | -13% | Stock Analytics | |
DIVIS LABORATORIES | ₹159,973.0 Cr | -1.6% | -1.8% | 17.9% | Stock Analytics | |
CIPLA | ₹124,507.0 Cr | -1.8% | 3.7% | -6% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹122,175.0 Cr | 0.7% | 2.4% | 3.4% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹104,355.0 Cr | -0.6% | 4.5% | -6.5% | Stock Analytics |
SYNCOM FORMULATIONS (INDIA) Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
SYNCOM FORMULATIONS (INDIA) | 1.5% |
-4.1% |
-17.9% |
SENSEX | 0.5% |
0.1% |
-2.1% |
You may also like the below Video Courses